FDAnews

SPP301 PHASE IIB DATA TO BE PRESENTED AT ANNUAL MEETING

Speedel has announced that data from its Phase IIb study of SPP301 in the treatment of diabetic nephropathy will be presented at the upcoming 38th Annual Meeting of the American Society of Nephrology in Philadelphia, Pa.

SPP301 is a once-daily oral endothelin A receptor antagonist, and was specifically optimized for improved liver safety. Speedel took the compound through a number of Phase I and exploratory Phase IIa clinical trials before selecting the novel indication of diabetic nephropathy for the Phase IIb clinical trial, the headline results for which were announced in March. A Phase III study began in July.